Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.

Tumoral plasma cells has retained stemness features and in particular, a polycomb-silenced gene expression signature. Therefore, epigenetic therapy could be a mean to fight for multiple myeloma (MM), still an incurable pathology. Deazaneplanocin A (DZNep), a S-adenosyl-L-homocysteine hydrolase inhib...

Full description

Bibliographic Details
Main Authors: Jérémie Gaudichon, Francesco Milano, Julie Cahu, Lætitia DaCosta, Anton C Martens, Jack-Michel Renoir, Brigitte Sola
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4177844?pdf=render